CSI Market
Sign In | Register

Milestone Pharmaceuticals Inc (MIST) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access MIST quarterly Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Milestone Pharmaceuticals Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-63.06
Depreciation & amortization0.11
Amortization of Other Assets0.43
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.65
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation7.46
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest3.41
Increase Decrease In Research And Development Tax Credits Receivable0.59
Accretion Amortization Expense Of Investment Discount Or Premium-0.08
Increase Decrease In License Receivable-1.55
Paid In Kind Interest For Royalty Financing Obligation-1.55
Increase Decrease In Operating Lease Right Of Use Asset Net-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-0.16
Increase (Decrease) in Accounts Payable4.43
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.03
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.53
Discontinued operations0.00
Net Cash flow from Operating Activities-49.04
Investing Activities
Capital Expenditures-0.30
Sale of Capital Items0.00
Payments to Acquire Short-term Investments11.55
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Sale Maturity And Collection Of Short Term Investments-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities11.25
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock58.78
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock9.50
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net14.67
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Proceeds From Issuance Of Private Placement Warrants-
Payments Of Warrant Issuance Costs-
Proceeds From Issuance Of Pre Funded Warrants Net Of Issuance Costs2.57
Proceeds From Royalty Financing Arrangement-
Payments Of Property And Equipment Financing-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities85.53
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-49.34
Total Cash Flow47.73
4 historic quarters locked

Sign in to unlock the full Milestone Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Milestone Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-032415

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License